Patents by Inventor Hitoshi Katada
Hitoshi Katada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059774Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: September 19, 2023Publication date: February 22, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroki HAYASHI, Hiroaki SUSUMU
-
Publication number: 20240043515Abstract: In one non-limiting embodiment, polypeptides comprising a variant Fc region which contains amino acid alterations in a parent Fc region, and methods for producing such polypeptides, are provided.Type: ApplicationFiled: August 27, 2021Publication date: February 8, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI
-
Publication number: 20240002510Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2022Publication date: January 4, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroki HAYASHI, Hiroaki SUSUMU, Shimon SAKAGUCHI
-
Publication number: 20230416371Abstract: In one non-limiting embodiment, polypeptides comprising a variant Fc region which contains amino acid alterations in a parent Fc region, and methods for producing such polypeptides, are provided.Type: ApplicationFiled: August 28, 2020Publication date: December 28, 2023Inventors: Hitoshi KATADA, Kanako TATSUMI
-
Publication number: 20230257470Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.Type: ApplicationFiled: April 11, 2023Publication date: August 17, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
-
Patent number: 11718678Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.Type: GrantFiled: March 2, 2020Date of Patent: August 8, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Yuki Iwayanagi, Tatsuhiko Tachibana, Futa Mimoto, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono
-
Publication number: 20230174655Abstract: An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of Fc?RIIa, types H and R, and having enhanced Fc?RIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of Fc?RIIa and enhancing the Fc?RIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances Fc?RIIb-binding activity, and maintains or decreases binding activities towards both allotypes of Fc?RIIa, types H and R.Type: ApplicationFiled: June 22, 2022Publication date: June 8, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Futa Mimoto, Taichi Kuramochi, Tomoyuki Igawa, Hitoshi Katada, Shojiro Kadono
-
Publication number: 20230140797Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.Type: ApplicationFiled: June 30, 2022Publication date: May 4, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, Hitoshi Katada, Shojiro Kadono, Futa Mimoto
-
Publication number: 20230058982Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: December 27, 2019Publication date: February 23, 2023Inventors: Hitoshi KATADA, Kanako TATSUMI, Kanako ATSUMI, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORII, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroaki SUSUMU
-
Publication number: 20230020377Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2022Publication date: January 19, 2023Inventors: Hitoshi KATADA, Kanako Tatsumi, Yutaka Matsuda, Shun Shimizu, Masaki Kamimura, Yasunori Komori, Yuji Hori, Tomoyuki Igawa, Hiroki Kawauchi, Hiroki Hayashi, Hiroaki Susumu, Shimon Sakaguchi
-
Publication number: 20220411483Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.Type: ApplicationFiled: February 14, 2022Publication date: December 29, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
-
Publication number: 20220315909Abstract: The present application relates to protease substrates, peptide sequences cleavable by a protease, polypeptides comprising a protease cleavage sequence and methods for production thereof, pharmaceutical compositions comprising a polypeptide comprising a protease cleavage sequence, and methods for releasing an antigen-binding domain or a ligand by the cleavage of a protease cleavage sequence included in a polypeptide.Type: ApplicationFiled: June 5, 2020Publication date: October 6, 2022Inventors: Mika SAKURAI, Tatsuya KAWA, Hitoshi KATADA, Naoka HIRONIWA
-
Patent number: 11454633Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: GrantFiled: June 1, 2020Date of Patent: September 27, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao Ruike, Taichi Kuramochi, Hiroyasu Muramatsu, Atsunori Ueyama, Tomoyuki Igawa, Hitoshi Katada, Yuji Hori
-
Patent number: 11267868Abstract: A polypeptide containing an antibody Fc region variant which has an amino acid sequence in which an amino acid alteration at position 238 according to EU numbering is combined with other specific amino acid alteration(s), was found to have decreased binding activities to all activating Fc?Rs, in particular Fc?RIIa (R type), while maintaining its Fc?RIIb-binding activity, when compared to a polypeptide containing a native IgG Fc region.Type: GrantFiled: April 2, 2014Date of Patent: March 8, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Futa Mimoto, Hitoshi Katada, Tomoyuki Igawa
-
Publication number: 20220010030Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond.Type: ApplicationFiled: September 24, 2021Publication date: January 13, 2022Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Hitoshi Katada, Yuji Hori, Shojiro Kadono
-
Patent number: 11142587Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating homo variants of plural types of heavy chain constant region-containing polypeptides differing in antigen-binding activity under a reducing condition that reorganize the inter-polypeptide disulfide bond between cysteine residues outside of core hinge regions. A feature of the production method of the present invention is that amino acid residues in the core hinge regions do not form any disulfide bond.Type: GrantFiled: March 31, 2016Date of Patent: October 12, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hitoshi Katada, Yuji Hori, Shojiro Kadono
-
Patent number: 11124576Abstract: It is intended to provide a method for efficiently and stably producing a heteromultimer by incubating, under a reducing condition, homo variants of plural types of polypeptides in which the alteration of amino acids that form the interface between Fc regions and/or the alteration to destabilize the stability of a heavy chain CH3 region has been introduced in the heavy chain CH3 regions so at to achieve the promotion of the dissociation of the Fc regions and/or the control of the association thereof through the use of charge repulsion.Type: GrantFiled: September 26, 2014Date of Patent: September 21, 2021Assignee: Chungai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hitoshi Katada, Futa Mimoto
-
Publication number: 20210261648Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).Type: ApplicationFiled: September 22, 2020Publication date: August 26, 2021Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
-
Patent number: 10919953Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).Type: GrantFiled: August 23, 2013Date of Patent: February 16, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
-
Publication number: 20200317768Abstract: The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.Type: ApplicationFiled: June 1, 2020Publication date: October 8, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Yoshinao RUIKE, Taichi KURAMOCHI, Hiroyasu MURAMATSU, Atsunori UEYAMA, Tomoyuki IGAWA, Hitoshi KATADA, Yuji HORI